JP2016513643A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513643A5
JP2016513643A5 JP2016501314A JP2016501314A JP2016513643A5 JP 2016513643 A5 JP2016513643 A5 JP 2016513643A5 JP 2016501314 A JP2016501314 A JP 2016501314A JP 2016501314 A JP2016501314 A JP 2016501314A JP 2016513643 A5 JP2016513643 A5 JP 2016513643A5
Authority
JP
Japan
Prior art keywords
protein
recombinant protein
tentacle
chromatography medium
anion exchange
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016501314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513643A (ja
JP6457479B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/023682 external-priority patent/WO2014159441A1/en
Publication of JP2016513643A publication Critical patent/JP2016513643A/ja
Publication of JP2016513643A5 publication Critical patent/JP2016513643A5/ja
Application granted granted Critical
Publication of JP6457479B2 publication Critical patent/JP6457479B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016501314A 2013-03-14 2014-03-11 漏出したアフィニティ精製リガンドの除去 Active JP6457479B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361785038P 2013-03-14 2013-03-14
US61/785,038 2013-03-14
PCT/US2014/023682 WO2014159441A1 (en) 2013-03-14 2014-03-11 Removal of leaked affinity purification ligand

Publications (3)

Publication Number Publication Date
JP2016513643A JP2016513643A (ja) 2016-05-16
JP2016513643A5 true JP2016513643A5 (enExample) 2017-03-30
JP6457479B2 JP6457479B2 (ja) 2019-01-23

Family

ID=50424772

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016501314A Active JP6457479B2 (ja) 2013-03-14 2014-03-11 漏出したアフィニティ精製リガンドの除去

Country Status (17)

Country Link
US (3) US20160024144A1 (enExample)
EP (3) EP4026596A1 (enExample)
JP (1) JP6457479B2 (enExample)
AU (1) AU2014240596B2 (enExample)
CA (1) CA2904411A1 (enExample)
CY (1) CY1120353T1 (enExample)
DK (2) DK3395423T3 (enExample)
ES (2) ES2674697T5 (enExample)
FI (1) FI3395423T3 (enExample)
HU (2) HUE064450T2 (enExample)
LT (2) LT3395423T (enExample)
MX (2) MX365501B (enExample)
PL (2) PL2969099T5 (enExample)
PT (2) PT3395423T (enExample)
SI (2) SI2969099T2 (enExample)
TR (1) TR201809050T4 (enExample)
WO (1) WO2014159441A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2969099T2 (sl) 2013-03-14 2022-04-29 Amgen Inc. Odstranjevanje izluženega afinitetnega purifikacijskega liganda
TWI596107B (zh) * 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
MA40232A (fr) * 2014-06-13 2017-04-19 Lupin Ltd Procédé de purification de la protéine de fusion tnfr:fc
CN105214341B (zh) * 2015-09-17 2017-12-15 广州康盛生物科技有限公司 组合型吸附柱及其制备方法
EP3436473A4 (en) * 2016-03-29 2019-10-23 Navya Biologicals Pvt. Ltd. METHOD FOR PURIFYING FC FUSION PROTEINS
WO2018146067A1 (en) 2017-02-09 2018-08-16 Bracco Suisse Sa Process for the purification of soluble psgl-1 protein variants
CN118047854B (zh) * 2024-02-26 2024-08-02 武汉鹰达生物科技有限公司 一种人载脂蛋白a-i的分离纯化方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
DE3811042A1 (de) 1988-03-31 1989-10-19 Merck Patent Gmbh Ionenaustauscher
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP0939121B2 (de) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
DE69332981T2 (de) 1992-10-23 2004-05-19 Immunex Corp., Seattle Methoden zur herstellung löslicher, oligomerer proteine
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
DE4333821A1 (de) 1993-10-04 1995-04-06 Merck Patent Gmbh Ionenaustauscher
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
DE19501726A1 (de) 1995-01-20 1996-07-25 Merck Patent Gmbh Polymerisationsfähige Derivate von Polyamiden
ES2253753T3 (es) 1995-06-29 2006-06-01 Immunex Corporation Citocina que induce apoptosis.
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
EP0906357B1 (de) 1996-06-21 2001-08-08 MERCK PATENT GmbH Polymere sorbentien auf basis polymerisationsfähiger derivate von polyamiden
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1998058253A1 (de) 1997-06-18 1998-12-23 Merck Patent Gmbh Verwendung monolithischer sorbentien für präparative chromatographische trennverfahren
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
DE60231651D1 (de) * 2001-12-21 2009-04-30 Immunex Corp Proteinreinigungsverfahren
EP1869065B1 (en) * 2005-03-11 2020-05-06 Wyeth LLC A method of weak partitioning chromatography
WO2008063892A2 (en) * 2006-11-08 2008-05-29 Wyeth Rationally designed media for cell culture
EP2406274A2 (en) * 2009-03-11 2012-01-18 Wyeth LLC Methods of purifying small modular immunopharmaceutical proteins
JP5980782B2 (ja) * 2010-07-30 2016-08-31 ファイザー・インク タンパク質のタンデム精製
US20140128577A1 (en) 2011-06-24 2014-05-08 Dr. Reddy's Laboratories Limited Purification of chimeric protein
BR112014000352A2 (pt) * 2011-07-08 2017-02-14 Merck Sharp & Dohe Corp método de purificar uma proteína de fusão-fc, proteínas de fusão contendo fc purificada, tnfr:fc purificada, e tnfr:fc elevadamente purificada
HRP20211773T1 (hr) * 2011-11-04 2022-03-04 Zymeworks Inc. Stabilna heterodimerni dizajn antitijela s mutacijama u fc domeni
SG10201701224UA (en) * 2012-03-12 2017-04-27 Merck Patent Gmbh Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode
SI2969099T2 (sl) 2013-03-14 2022-04-29 Amgen Inc. Odstranjevanje izluženega afinitetnega purifikacijskega liganda

Similar Documents

Publication Publication Date Title
JP2016513643A5 (enExample)
JP2012018171A5 (enExample)
JP2017086090A5 (enExample)
JP2017508759A5 (enExample)
JP2017524740A5 (enExample)
JP2014500311A5 (enExample)
JP2015051975A5 (enExample)
JP2015506926A5 (enExample)
RU2014111820A (ru) Способы элиминации вируса
JP2016530533A5 (enExample)
FI3395423T3 (fi) Vuotaneen affiniteettipuhdistusligandin poistaminen
JP2010534336A5 (enExample)
JP2012515160A5 (enExample)
JP2014501758A5 (enExample)
JP2016502843A5 (enExample)
JP2014502272A5 (enExample)
US20110166332A1 (en) Enhanced antibody aggregate removal with capto adhere in the presence of protein-excluded zwitterions
US20120283419A1 (en) Separation of protein monomers from aggregates by solid weak anion exchange support functionalized with amine moieties
JP2015537212A5 (enExample)
JP2014532718A5 (enExample)
Dhadge et al. Magnetic aqueous two phase fishing: a hybrid process technology for antibody purification
JP2018516229A5 (enExample)
HRP20180182T1 (hr) Pravilno presavijeni etanercept visoke čistoće i izvanrednog prinosa
EA201892522A1 (ru) Днк-моноклональные антитела, нацеленные на молекулы контрольных точек
JP2015503524A5 (enExample)